Researchers from the Department of Clinical Neurosciences, the Hotchkiss Brain Institute, and the University of Calgary, just published results of a study to compare adverse effects, tolerability and efficacy of the tricyclic antidepressants (TCAs) amitriptyline and nortriptyline in management of neuropathic pain due to peripheral neuropathy (PN). Their results show that amitriptyline and nortriptyline are equivalent for overall adverse effects and discontinuation rates. Either TCA should be equally considered for use in neuropathic pain due to PN. READ MORE
Source:Â John Wiley & Sons A/S